WANY
CRDL

Wealthspire Advisors (New York)’s Cardiol Therapeutics CRDL Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1K Hold
15,151
– – ﹤0.01% 1274
2026
Q1 		$20.5K Hold
15,151
– – ﹤0.01% 924
2025
Q4 		$14.5K Buy
+15,151
New +$15.9K ﹤0.01% 1032
2025
Q3 		– Sell
-15,151
Closed -$20.6K – 3063
2025
Q2 		$20.6K Hold
15,151
– – ﹤0.01% 843
2025
Q1 		$14.7K Hold
15,151
– – ﹤0.01% 785
2024
Q4 		$19.4K Sell
15,151
-15,151
-50% -$25.5K ﹤0.01% 789
2024
Q3 		$60K Buy
+30,302
New +$62.9K ﹤0.01% 737

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wealthspire Advisors (New York)'s CRDL Position: Q2 2026 in Review

Wealthspire Advisors (New York) held its Cardiol Therapeutics (CRDL) position steady in Q2 2026 at 15,151 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1274.

Wealthspire Advisors (New York) first reported a position in CRDL in Q3 2024 and has held it in 7 quarters since. The position peaked at $60K in Q3 2024. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Wealthspire Advisors (New York) held 15,151 shares of Cardiol Therapeutics worth $16.1K as of Q2 2026.
  • Wealthspire Advisors (New York) left its Cardiol Therapeutics share count unchanged in Q2 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #1274 holding.
  • Wealthspire Advisors (New York) first reported a position in Cardiol Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Wealthspire Advisors (New York)'s Cardiol Therapeutics position peaked at $60K in Q3 2024.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.